Lab
Quest Diagnostics Clinical Laboratories INC
Quest Diagnostics Clinical Laboratories INC was paid $3.66M by Medicaid between Jan 2018 and May 2022, across 23 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 51% of everything it billed.
33Billing provider infoQUEST DIAGNOSTICS CLINICAL LABORATORIES INC
TUCKER, GA 30084
TUCKER, GA 30084
33aNPI1841339918assigned 02/06/2007
33bProvider typeClinical Medical Laboratory
28Total paid$3.66M
24GClaims98,626
24DCodes billed23
24AFirst – last monthJan 2018 – May 2022
Compared with peers
Next to other Clinical Medical Laboratory providers in Georgia
Rank by total paid#12 of 66
Median peer was paid$178K
This provider vs. median21×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official BOWLES, CHARLES controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 61,077 | $2.02M | |
| 2019 | 34,114 | $1.46M | |
| 2020 | 3,334 | $171K | |
| 2021 | 36 | $458.34 | |
| 2022 | 65 | $0.00 |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 51% | 44,403 | 33,018 | $1.86M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 39% | 26,754 | 20,104 | $1.44M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 3.6% | 1,917 | 1,273 | $132K |
| 80360 | 1.2% | 3,515 | 1,520 | $44K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 801 | 583 | $29K |
| 80361 | <1% | 2,435 | 1,822 | $27K | |
| 80365 | <1% | 2,439 | 1,830 | $27K | |
| 80346 | <1% | 2,521 | 1,413 | $23K | |
| 80349 | <1% | 2,364 | 1,458 | $22K | |
| 80355 | <1% | 3,799 | 1,008 | $9K | |
| 80324 | <1% | 1,007 | 684 | $9K | |
| 80348 | <1% | 3,052 | 695 | $8K |
11 more codes
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBOWLES, CHARLES (VICE PRESIDENT)
Parent organizationQUEST DIAGNOSTICS INCORPORATED
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.